Cite
HARVARD Citation
Miglietta, F. et al. (2020). Validation of Residual Proliferative Cancer Burden as a Predictor of Long‐Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer. Oncologist. pp. e1355-e1362. [Online].